{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(2)"],"submitter":["Ma YJ"],"pubmed_abstract":["Patients with relapsed/refractory acute myeloid leukemia (R/R AML) often show resistance to chemotherapy and have dismal outcomes. Therefore, it is urgent to develop new treatment strategies to address this problem. With tremendous achievement of chimeric antigen receptor T cells (CAR-T) therapy against B-cell malignancies, many efforts have been devoted to developing CAR-T therapy for R/R AML but with limited success, in part owing to a lack of specific targets. C-type lectin-like molecule-1 (CLL-1) is highly expressed on AML blasts with no expression on normal hematopoietic stem cells, which makes it an ideal target of immunotherapy for AML. Here, we report 2 R/R AML patients who relapsed after allogeneic stem cell transplantation and failed multiline salvage therapies including anti-CD3"],"journal":["American journal of cancer research"],"pagination":["615-621"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8899985"],"repository":["biostudies-literature"],"pubmed_title":["Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment."],"pmcid":["PMC8899985"],"pubmed_authors":["Kang LQ","Qiu HY","Yu L","Cui QY","Liu DD","Cui W","Qu CJ","Dai HP","Zhu XM","Zhu WJ","Liu TH","Wu DP","Ma YJ","Tang XW","Shen HJ","Zhu MQ","Feng YF"],"additional_accession":[]},"is_claimable":false,"name":"Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment.","description":"Patients with relapsed/refractory acute myeloid leukemia (R/R AML) often show resistance to chemotherapy and have dismal outcomes. Therefore, it is urgent to develop new treatment strategies to address this problem. With tremendous achievement of chimeric antigen receptor T cells (CAR-T) therapy against B-cell malignancies, many efforts have been devoted to developing CAR-T therapy for R/R AML but with limited success, in part owing to a lack of specific targets. C-type lectin-like molecule-1 (CLL-1) is highly expressed on AML blasts with no expression on normal hematopoietic stem cells, which makes it an ideal target of immunotherapy for AML. Here, we report 2 R/R AML patients who relapsed after allogeneic stem cell transplantation and failed multiline salvage therapies including anti-CD3","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-30T23:53:30.83Z","creation":"2025-04-04T23:29:02.079Z"},"accession":"S-EPMC8899985","cross_references":{"pubmed":["35261791"]}}